UNASSIGNED: 181 Background: Studies on 15-year Post-RP survival including data on PSA relapse (PSA- @entity4632 ) are rare. We established the 15-year post-RP @entity263 specific mortality (PCSM), to explore the time to PSA- @entity4632 and PCSM thereafter, and to identify clinically available prognostic factors. METHODS: In @entity1 prostatectomized from 1987-2004 slightly modified D Amico risk groups were identified (T1: No palpable @entity5 ;"T2 unilateral"/"T2 bilateral" according to @entity5 palpability in one or both lobes). PSA - @entity4632 was defined as PSA >= 4   g/l before 2000, and thereafter as PSA >0.2   g/l. Delay of RP was defined as RP performance 3-12 months after diagnosis. Competing risk modeling was performed with a significance level of <0.05. RESULTS: After a median observation time of 12 years (range: 0-22), of 309 @entity1 (median age:62 years [range:40-74]) 40 have died from @entity263 ( @entity263 ) and 68 due to other causes (15-year PCSM: 15% [95%CI: 10-19%). No difference of PCSM was found between the low (N: 12) and the intermediate group (N: 121), the "conventional" high risk group ( N: 121) displaying a 24% PCSM rate (95% CI:16-32%) with particularly poor prognosis for @entity1 who presented with two high risk factors ( N. 32 ; PCSM: 33% [95% CI:20-46%]). The median time to PSA relapse (N: 152) was 5 years (range: 0-17), the median overall survival time after PSA- @entity4632 being 7 years (range: 0-17). PCSM continued to increase after 10 years. Delay of RP had no impact on PCSM. CONCLUSIONS: After a median observation time of 12 years approximately 1 of 7 @entity1 with localized @entity263 , most of them diagnosed before the PSA- era, have died of @entity263 . The "conventional" high-risk group is prognostically heterogeneous: @entity1 with two high risk criteria have a particularly poor prognosis. PSA- @entity4632 10 years after RP is no rare event followed by survival times of >10 years. Delay of RP for up to one year had no impact on PCSM.

15-year survival after radical prostatectomy (RP): Which prognostic factors are available for XXXX counseling?

@entity4632 :: ('5966', 'Gene') :: ['Rel'] @entity1 :: ('9606', 'Species') :: ['Men', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'PCa'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity1 :: (9606,Species) :: ['patient']
